Article Details

Pfizer's Lorbrena shows PFS improvement in Phase III lung cancer trial

Retrieved on: 2022-04-11 14:12:56

Tags for this article:

Click the tags to see associated articles and topics

Pfizer's Lorbrena shows PFS improvement in Phase III lung cancer trial. View article details on hiswai:

Excerpt

Pfizer has reported that Lorbrena demonstrated PFS improvement in first-line ALK-positive lung cancer patients in Phase III CROWN trial.

Article found on: www.clinicaltrialsarena.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up